BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Wainua (Eplontersen) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Wainua (Eplontersen)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05071300-10798@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05071300)
DESCRIPTION:Wainua (Eplontersen)\, phase 3.\nStudy: A Study to Assess the L
 ong-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884\
 , IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyret
 in-Mediated Amyloid Polyneuropathy\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eplontersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05071300
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05667493-10798@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Wainua (Eplontersen): Phase 3 readout est. (NCT05667493)
DESCRIPTION:Wainua (Eplontersen)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: An Extension Study to Assess Long-Term Safety of 
 Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (
 ATTR-CM)\nEstimated primary completion: August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eplontersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05667493
URL:https://assetmemo.bio/drug/eplontersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
